Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

AZ, Daiichi’s targeted breast cancer therapy on target

AstraZeneca and Daiichi Sankyo have presented new mid-stage data showing “clinically meaningful” responses in patients with advanced breast cancer taking trastuzumab deruxtecan.

The pivotal Phase II, single-arm DESTINY-Breast01 trial is assessing trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC), in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens.

The primary endpoint of objective response rate (ORR), confirmed by independent central review, was 60.9% with trastuzumab deruxtecan monotherapy. Patients had a median of six prior therapies for metastatic disease (2-27).

Patients achieved a disease control rate (DCR) of 97.3% with a median duration of response (DoR) of 14.8 months and median progression-free survival (PFS) of 16.4 months. The median overall survival (OS) has not yet been reached, with an estimated survival rate of 86% at one year, the firms said.

“The clinically meaningful and durable responses seen among these patients illustrate the potential of trastuzumab deruxtecan to establish a new standard of care,” said José Baselga, executive vice president, Oncology R&D, at AstraZeneca, commenting on the results.

“These results are impressive, as women with this advanced stage of breast cancer have already endured multiple prior therapies for HER2-positive metastatic breast cancer.”

Principal investigator Ian Krop, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, said the results are “particularly striking” as the drug “prompted a high level of durable tumour reduction among patients, the majority of whom had exhausted most if not all standard therapies for HER2-metastatic breast cancer”.

Trastuzumab deruxtecan is under priority review in the US for the treatment of patients with HER2-positive metastatic breast cancer, while a regulatory submission has also been made to Japan’s Ministry of Health, Labour and Welfare.

12th December 2019

http://www.pharmatimes.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company